Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia

C. Imai, K. Mihara, Martin Andreansky, I. C. Nicholson, C. H. Pui, T. L. Geiger, Dario Campana

Research output: Contribution to journalArticle

348 Citations (Scopus)

Abstract

To develop a therapy for drug-resistant B-lineage acute lymphoblastic leukemia (ALL), we transduced T lymphocytes with anti-CD19 chimeric receptors, consisting of an anti-CD19 single-chain variable domain (reactive with most ALL cases), the hinge and transmembrane domains of CD8α, and the signaling domain of CD3ζ. We compared the antileukemic activity mediated by a novel receptor ('anti-CD19-BB-ζ') containing the signaling domain of 4-1BB (CD137; a crucial molecule for T-cell antitumor activity) to that of a receptor lacking costimulatory molecules. Retroviral transduction produced efficient and durable receptor expression in human T cells. Lymphocytes expressing anti-CD19-BB-ζ receptors exerted powerful and specific cytotoxicity against ALL cells, which was superior to that of lymphocytes with receptors lacking 4-1BB. Anti-CD19-BB-ζ lymphocytes were remarkably effective in cocultures with bone marrow mesenchymal cells, and against leukemic cells from patients with drug-resistant ALL: as few as 1% anti-CD19-BB-ζ-transduced T cells eliminated most ALL cells within 5 days. These cells also expanded and produced interleukin-2 in response to ALL cells at much higher rates than those of lymphocytes expressing equivalent receptors lacking 4-1BB. We conclude that anti-CD19 chimeric receptors containing 4-1BB are a powerful new tool for T-cell therapy of B-lineage ALL and other CD19+ B-lymphoid malignancies.

Original languageEnglish
Pages (from-to)676-684
Number of pages9
JournalLeukemia
Volume18
Issue number4
DOIs
StatePublished - Apr 1 2004
Externally publishedYes

Fingerprint

CD137 Antigens
Precursor Cell Lymphoblastic Leukemia-Lymphoma
T-Lymphocytes
Lymphocytes
Cell- and Tissue-Based Therapy
Coculture Techniques
Bone Marrow Cells
Interleukin-2

Keywords

  • Acute lymphoblastic leukemia
  • B-cell lymphoma
  • CD137
  • T-cell receptor

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Cite this

Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. / Imai, C.; Mihara, K.; Andreansky, Martin; Nicholson, I. C.; Pui, C. H.; Geiger, T. L.; Campana, Dario.

In: Leukemia, Vol. 18, No. 4, 01.04.2004, p. 676-684.

Research output: Contribution to journalArticle

Imai, C. ; Mihara, K. ; Andreansky, Martin ; Nicholson, I. C. ; Pui, C. H. ; Geiger, T. L. ; Campana, Dario. / Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. In: Leukemia. 2004 ; Vol. 18, No. 4. pp. 676-684.
@article{f7d8e8306fa948999db879377795c5b5,
title = "Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia",
abstract = "To develop a therapy for drug-resistant B-lineage acute lymphoblastic leukemia (ALL), we transduced T lymphocytes with anti-CD19 chimeric receptors, consisting of an anti-CD19 single-chain variable domain (reactive with most ALL cases), the hinge and transmembrane domains of CD8α, and the signaling domain of CD3ζ. We compared the antileukemic activity mediated by a novel receptor ('anti-CD19-BB-ζ') containing the signaling domain of 4-1BB (CD137; a crucial molecule for T-cell antitumor activity) to that of a receptor lacking costimulatory molecules. Retroviral transduction produced efficient and durable receptor expression in human T cells. Lymphocytes expressing anti-CD19-BB-ζ receptors exerted powerful and specific cytotoxicity against ALL cells, which was superior to that of lymphocytes with receptors lacking 4-1BB. Anti-CD19-BB-ζ lymphocytes were remarkably effective in cocultures with bone marrow mesenchymal cells, and against leukemic cells from patients with drug-resistant ALL: as few as 1{\%} anti-CD19-BB-ζ-transduced T cells eliminated most ALL cells within 5 days. These cells also expanded and produced interleukin-2 in response to ALL cells at much higher rates than those of lymphocytes expressing equivalent receptors lacking 4-1BB. We conclude that anti-CD19 chimeric receptors containing 4-1BB are a powerful new tool for T-cell therapy of B-lineage ALL and other CD19+ B-lymphoid malignancies.",
keywords = "Acute lymphoblastic leukemia, B-cell lymphoma, CD137, T-cell receptor",
author = "C. Imai and K. Mihara and Martin Andreansky and Nicholson, {I. C.} and Pui, {C. H.} and Geiger, {T. L.} and Dario Campana",
year = "2004",
month = "4",
day = "1",
doi = "10.1038/sj.leu.2403302",
language = "English",
volume = "18",
pages = "676--684",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia

AU - Imai, C.

AU - Mihara, K.

AU - Andreansky, Martin

AU - Nicholson, I. C.

AU - Pui, C. H.

AU - Geiger, T. L.

AU - Campana, Dario

PY - 2004/4/1

Y1 - 2004/4/1

N2 - To develop a therapy for drug-resistant B-lineage acute lymphoblastic leukemia (ALL), we transduced T lymphocytes with anti-CD19 chimeric receptors, consisting of an anti-CD19 single-chain variable domain (reactive with most ALL cases), the hinge and transmembrane domains of CD8α, and the signaling domain of CD3ζ. We compared the antileukemic activity mediated by a novel receptor ('anti-CD19-BB-ζ') containing the signaling domain of 4-1BB (CD137; a crucial molecule for T-cell antitumor activity) to that of a receptor lacking costimulatory molecules. Retroviral transduction produced efficient and durable receptor expression in human T cells. Lymphocytes expressing anti-CD19-BB-ζ receptors exerted powerful and specific cytotoxicity against ALL cells, which was superior to that of lymphocytes with receptors lacking 4-1BB. Anti-CD19-BB-ζ lymphocytes were remarkably effective in cocultures with bone marrow mesenchymal cells, and against leukemic cells from patients with drug-resistant ALL: as few as 1% anti-CD19-BB-ζ-transduced T cells eliminated most ALL cells within 5 days. These cells also expanded and produced interleukin-2 in response to ALL cells at much higher rates than those of lymphocytes expressing equivalent receptors lacking 4-1BB. We conclude that anti-CD19 chimeric receptors containing 4-1BB are a powerful new tool for T-cell therapy of B-lineage ALL and other CD19+ B-lymphoid malignancies.

AB - To develop a therapy for drug-resistant B-lineage acute lymphoblastic leukemia (ALL), we transduced T lymphocytes with anti-CD19 chimeric receptors, consisting of an anti-CD19 single-chain variable domain (reactive with most ALL cases), the hinge and transmembrane domains of CD8α, and the signaling domain of CD3ζ. We compared the antileukemic activity mediated by a novel receptor ('anti-CD19-BB-ζ') containing the signaling domain of 4-1BB (CD137; a crucial molecule for T-cell antitumor activity) to that of a receptor lacking costimulatory molecules. Retroviral transduction produced efficient and durable receptor expression in human T cells. Lymphocytes expressing anti-CD19-BB-ζ receptors exerted powerful and specific cytotoxicity against ALL cells, which was superior to that of lymphocytes with receptors lacking 4-1BB. Anti-CD19-BB-ζ lymphocytes were remarkably effective in cocultures with bone marrow mesenchymal cells, and against leukemic cells from patients with drug-resistant ALL: as few as 1% anti-CD19-BB-ζ-transduced T cells eliminated most ALL cells within 5 days. These cells also expanded and produced interleukin-2 in response to ALL cells at much higher rates than those of lymphocytes expressing equivalent receptors lacking 4-1BB. We conclude that anti-CD19 chimeric receptors containing 4-1BB are a powerful new tool for T-cell therapy of B-lineage ALL and other CD19+ B-lymphoid malignancies.

KW - Acute lymphoblastic leukemia

KW - B-cell lymphoma

KW - CD137

KW - T-cell receptor

UR - http://www.scopus.com/inward/record.url?scp=3042551216&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042551216&partnerID=8YFLogxK

U2 - 10.1038/sj.leu.2403302

DO - 10.1038/sj.leu.2403302

M3 - Article

C2 - 14961035

AN - SCOPUS:3042551216

VL - 18

SP - 676

EP - 684

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 4

ER -